Aura Biosciences Announces Pricing of Initial Public Offering
29 October 2021 - 12:39PM
Business Wire
Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology
company developing a novel class of virus-like drug conjugate
therapies for multiple oncology indications, today announced the
pricing of its initial public offering of 5,400,000 shares of
common stock at a public offering price of $14.00 per share. The
gross proceeds of the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
Aura, are expected to be $75.6 million. All of the shares are being
offered by Aura. In addition, Aura has granted the underwriters a
30-day option to purchase up to an additional 810,000 shares of
common stock at the initial public offering price less underwriting
discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global
Market on October 29, 2021 under the ticker symbol “AURA.” The
offering is expected to close on November 2, 2021, subject to the
satisfaction of customary closing conditions.
Cowen, SVB Leerink and Evercore ISI are acting as joint
book-running managers for the offering, and BTIG is acting as lead
manager for the offering.
The registration statements relating to these securities became
effective on October 28, 2021. The offering will be made only by
means of a prospectus, copies of which may be obtained from Cowen
and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com; SVB Leerink LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@svbleerink.com; or Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York,
New York 10055; by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage oncology company
developing a novel technology platform based on virus-like drug
conjugates (VDCs) to target and destroy cancer cells selectively
while activating the immune system to create long lasting
anti-tumor immunity. The VDC technology platform is based on the
discoveries of NIH Distinguished Investigator Dr. John Schiller of
the Center for Cancer Research at the National Cancer Institute.
The company has the goal of developing this technology in multiple
cancer indications with an initial focus on primary choroidal
melanoma, a rare disease for which there are no approved drugs.
Aura’s lead product candidate belzupacap sarotalocan (AU-011) is
currently in Phase 2 development for the first line treatment of
primary choroidal melanoma, a vision and life-threatening form of
eye cancer where standard of care radioactive treatments leave
patients with major vision loss and severe comorbidities. AU-011
was well tolerated in a Phase 1b/2 trial, demonstrating high rates
of tumor control and vision preservation. Future pipeline
applications for Aura’s technology include additional ocular
oncology indications like choroidal metastases and solid tumor
indications like non-muscle invasive bladder cancer. Aura is
headquartered in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211028006309/en/
Investor and Media Contact: Matthew DeYoung Argot
Partners 212-600-1902 | aura@argotpartners.com
Aura Energy (LSE:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Energy (LSE:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024